Sarah Moharem-Elgamal, Anna Baritussio, Ruxandra Christodorescu, Marc Ferrini, Giovanni Benfari, Fabrizio Ricci, Filipa Xavier Valente, José F Rodríguez Palomares, Gianluca Pontone, Stefano Nistri
{"title":"Implementation of cardiac magnetic resonance imaging in everyday cardiology practice","authors":"Sarah Moharem-Elgamal, Anna Baritussio, Ruxandra Christodorescu, Marc Ferrini, Giovanni Benfari, Fabrizio Ricci, Filipa Xavier Valente, José F Rodríguez Palomares, Gianluca Pontone, Stefano Nistri","doi":"10.1093/eurheartj/ehag678","DOIUrl":"https://doi.org/10.1093/eurheartj/ehag678","url":null,"abstract":"Cardiac magnetic resonance (CMR) plays an established role in the assessment of cardiac patients. In this document, the aim is to demonstrate and clarify the role of CMR in the clinical management of heart disease for general cardiologists in everyday clinical practice. This document will cover the clinical indications, prognostic values, and limitations of CMR in the diagnosis and follow-up of heart disease, including ischaemic heart disease, heart failure, cardiomyopathies, valvular heart disease, aortopathies, cardiac masses, pericardial conditions, and adult congenital heart disease. This document also provides a basic understanding of the use of different CMR sequences and how cardiac function is assessed. With the increasing number of patients with cardiac implantable electronic devices, a brief understanding and advice on the use of CMR in this growing patient population who may need a scan during their lifetime is discussed. This document outlines the clinical applications of CMR and its use in everyday clinical practice for cardiologists who are not experts in CMR.","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":"16 1","pages":""},"PeriodicalIF":39.3,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149077582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Casey P Shannon, Sara Assadian, Ashwini Rajasekaran, Chengliang Yang, Estefanía Espín, Le Lam, Robert Balshaw, Michael A Seidman, Chi K Lai, Heather J Ross, Marshall P Hyden, Sharon S Y Chih, Mustafa Toma, Bruce M McManus, Raymond T Ng, Scott J Tebbutt
{"title":"Acute cellular rejection after heart transplantation: validation of HEARTBiT, a transcriptomic biomarker.","authors":"Casey P Shannon, Sara Assadian, Ashwini Rajasekaran, Chengliang Yang, Estefanía Espín, Le Lam, Robert Balshaw, Michael A Seidman, Chi K Lai, Heather J Ross, Marshall P Hyden, Sharon S Y Chih, Mustafa Toma, Bruce M McManus, Raymond T Ng, Scott J Tebbutt","doi":"10.1093/eurheartj/ehag751","DOIUrl":"https://doi.org/10.1093/eurheartj/ehag751","url":null,"abstract":"<p><strong>Background and aims: </strong>Acute cellular rejection (ACR) risk is highest within 60 days of heart transplantation (HTx), yet existing minimally invasive surveillance tools lack validation for this high-risk period. This study prospectively validated the diagnostic accuracy of HEARTBiT, a transcriptomic biomarker for detecting moderate-to-severe ACR, including during the early post-operative period.</p><p><strong>Methods: </strong>This prospective diagnostic accuracy study (NCT03575910) enrolled consecutive adult HTx recipients at four tertiary clinical centres. The diagnostic performance of HEARTBiT was evaluated in 336 visits from 117 participants against centralized expert consensus panel endomyocardial biopsy grades. An exploratory analysis of 246 serial visits from 31 participants evaluated the prognostic potential of tracking individual transcriptomic trajectories over time.</p><p><strong>Results: </strong>HEARTBiT accurately detected moderate-to-severe ACR (ISHLT ≥2R) with an overall area under the curve (AUC) of 0.78 [95% confidence interval (CI) 0.70-0.86]. Performance was stable early post-HTx (≤60 days: AUC = 0.78, 95% CI 0.65-0.90) and beyond 60 days (AUC = 0.80, 95% CI 0.72-0.87). Prioritizing high sensitivity (89% early, 100% late; corresponding to ≤1 missed ACR overall) yielded a specificity of 56% in the early period (≤60 days) and 49% beyond 60 days using the pre-specified cutoff (>0.54). Alternatively, adopting an exploratory time-varying threshold (>0.68) beyond 60 days yielded 83% sensitivity and 76% specificity. Importantly, HEARTBiT scores increased weeks before histological detection of ACR by tissue biopsy (slope-based AUC = 0.78, 95% CI 0.60-0.96).</p><p><strong>Conclusions: </strong>HEARTBiT provides a reliable, minimally invasive rule-out signal for moderate-to-severe ACR across the first year post-HTx, particularly during the high-risk early post-operative period. Serial tracking of HEARTBiT score trajectories has potential for prognosis of progression to ACR. These findings support the clinical utility of this biomarker in safely sparing more than 50% of protocol surveillance endomyocardial biopsies.</p>","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":" ","pages":""},"PeriodicalIF":45.3,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149073296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Flavio L Ribichini, Roberto Scarsini, Giuseppe Tarantini
{"title":"Post-TAVI FFR: a continuum between epicardial and microvascular physiology.","authors":"Flavio L Ribichini, Roberto Scarsini, Giuseppe Tarantini","doi":"10.1093/eurheartj/ehag779","DOIUrl":"https://doi.org/10.1093/eurheartj/ehag779","url":null,"abstract":"","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":" ","pages":""},"PeriodicalIF":45.3,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149073758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Charlotte J Teunis, Thomas J C Collins, Reindert F Oostveen, Annette E Neele, Menno de Winther, Nick S Nurmohamed, Jarom Heijmans, Maaike Winkelmeijer, Kim E Dzobo, Mark E Cooper, Daniël H van Raalte, Max Nieuwdorp, Hein J Verberne, Erik S G Stroes, Andrew J Murphy, Jeffrey Kroon, Nordin M J Hanssen
{"title":"Potential bone marrow-driven reduction of circulating inflammatory monocytes by semaglutide in Type 2 diabetes.","authors":"Charlotte J Teunis, Thomas J C Collins, Reindert F Oostveen, Annette E Neele, Menno de Winther, Nick S Nurmohamed, Jarom Heijmans, Maaike Winkelmeijer, Kim E Dzobo, Mark E Cooper, Daniël H van Raalte, Max Nieuwdorp, Hein J Verberne, Erik S G Stroes, Andrew J Murphy, Jeffrey Kroon, Nordin M J Hanssen","doi":"10.1093/eurheartj/ehag627","DOIUrl":"https://doi.org/10.1093/eurheartj/ehag627","url":null,"abstract":"<p><strong>Background and aims: </strong>Glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce cardiovascular disease (CVD) in type 2 diabetes (T2D) and have anti-inflammatory effects in experimental studies, but their mechanism of action in humans remains unclear. This study characterized the cardiovascular-haematopoietic axis in individuals with T2D receiving semaglutide, as a potential mediator of GLP-1RA cardioprotective properties.</p><p><strong>Methods: </strong>In 16 individuals with T2D [63.2 ± 6.1 years, 37.5% female, weight 82.3 ± 15.3 kg, body mass index (BMI) 28.33 ± 3.5 kg/m2, LDL cholesterol 2.2 ± 0.9 mmol/L, glycated haemoglobin (HbA1c) 78.1 ± 13.1 mmol/mol, high-sensitivity C-reactive protein (hsCRP) 1.9 (1.2, 5.8) mg/L], blood and sternal bone marrow aspirates (subset, n = 14) were collected at baseline and after 6 months of semaglutide ≤2.0 mg weekly. Circulating monocytes and haematopoietic precursors were quantified by flow cytometry, plasma cytokines using an nELISA™ assay (Nomic Bio) and inflammatory macrophages in coronary arteries, bone marrow, and spleen by gallium-68-labelled DOTA-(Tyr3)-octreotate (68Ga-DOTATATE) positron emission tomography-computed tomography scans.</p><p><strong>Results: </strong>After 6 months of semaglutide, significant reductions in HbA1c (-21.1 mmol/mol, P < .0001), weight (-6.7 kg, P < .001), BMI (-2.5 kg/m2, P < .001), and hsCRP (-1.0 mg/L, P = .005) were observed. Circulating CD16+ monocytes were markedly lower (-18.8%, P = .034), with increased bone marrow retention correlating with weight loss, alongside reductions in interleukin-1 receptor antagonist, leptin, E-selectin, intercellular adhesion molecule-1 (ICAM-1), C-C motif chemokine ligand 2, C-C motif chemokine ligand 11, and C-X-C motif chemokine ligand 13. Gallium-68-labelled DOTA-(Tyr3)-octreotate PET-CT showed lower bone marrow uptake (-17.5%, P = .037), but not in spleen or coronary arteries.</p><p><strong>Conclusions: </strong>Semaglutide in T2D potentially reduces circulating inflammatory monocytes, increases bone marrow retention, and lowers markers of endothelial inflammation, with no reduction in coronary artery inflammatory macrophages. Semaglutide is associated with lower bone marrow 68Ga-DOTATATE uptake, which may relate to anti-inflammatory effects relevant to CVD risk.</p>","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":" ","pages":""},"PeriodicalIF":45.3,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149073797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Correction to: Familial hypercholesterolaemia in children and adolescents: a European Atherosclerosis Society consensus statement.","authors":"","doi":"10.1093/eurheartj/ehag759","DOIUrl":"https://doi.org/10.1093/eurheartj/ehag759","url":null,"abstract":"","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":" ","pages":""},"PeriodicalIF":45.3,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149079908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Correction: PCSK9 inhibitor treatment and outcomes in patients with atherosclerotic cardiovascular disease but without prior ischaemic events: an observational study.","authors":"","doi":"10.1093/eurheartj/ehag791","DOIUrl":"https://doi.org/10.1093/eurheartj/ehag791","url":null,"abstract":"","PeriodicalId":11976,"journal":{"name":"European Heart Journal","volume":" ","pages":""},"PeriodicalIF":45.3,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149069541","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}